The presence of genetic alterations in the tyrosine kinase domain of the oncogene (eg. EGFR and ALK) is associated with the clinical response to tyrosine kinase inhibitors (TKIs) in patients with non-small cell lung cancers. Therefore, the detection of altered genetic alterations is useful for predicting the treatment response for TKIs in non-small cell lung cancer patients. However, good quality tumor tissues are available only in \<50% of patients with inoperable lung cancer for mutation analysis. In this study, the investigators will detect and quantify the genetic alterations in plasma. the investigators will investigate if the serial measurement of cancer-derived genetic alterations in plasma can provide a means for monitoring disease progression, as well as treatment response. In addition the investigators will analysis the resistant mechanism of TKIs and chemotherapy with plasma tumor DNA.
Study Type
OBSERVATIONAL
Enrollment
200
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea
Detection of genetic alterations (including EGFR and ALK) in plasma samples
To evaluate the sensitivity of digital PCR to detect the genetic alterations in plasma tumor DNA
Time frame: 60 months
Quantifying circulating tumor DNA in serially collected plasma specimens
To evaluate the change of quantity of circulating tumor DNA with digital PCR
Time frame: 60 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.